Tibsovo (ivosidenib) targets a specific gene mutation called IDH1, which can affect your bone marrow. IDH1 mutation prevents young blood cells from developing into healthy adult blood cells, which can result in symptoms of acute myeloid leukemia (AML).
Tibsovo is used to treat AML in adults with an IDH1 mutation. Your doctor will test you for this gene. Ivosidenib is used when other treatments did not work or have stopped working.
Tibsovo is also used in adults 75 years and older who have newly-diagnosed AML and cannot use certain chemotherapy treatments because of other health problems.
